Amarin (AMRN) Stock Price, News & Analysis

Company Overview

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events. Since its initial U.S. approval in 2012, Vascepa has received marketing authorizations in key markets including Canada, the European Union and Japan, often through strategic partnerships with regional pharmaceutical companies. Amarin manages its own commercial organization in the United States and leverages licensing agreements to support distribution and patient access abroad.

In addition to its marketed portfolio, Amarin is conducting ongoing research to explore new indications for Vascepa and to expand its understanding of lipid-modifying therapies. Its clinical programs aim to investigate potential benefits in a range of cardiovascular and metabolic conditions. The company operates with a leadership team comprised of seasoned professionals in biopharmaceutical R&D, regulatory affairs and commercial strategy, supported by research facilities in the United States and Europe.

Key Stats

• Today's Range: $19.31 to $20.90
• 50-Day Range: $14.60 to $20.25
• 52-Week Range: $7.08 to $20.90
• Volume: 609,079 shs
• Average Volume: 114,518 shs
• Market Capitalization: $407.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Hold

Amarin Stock Analysis - MarketRank™

Amarin scored higher than 21% of companies evaluated by MarketBeat, and ranked 844th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Amarin has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, no hold ratings, and 2 sell ratings.

Downside Risk

Amarin has a consensus price target of $12.00, representing about 39.1% downside from its current price of $19.72.

Amount of Analyst Coverage

Amarin has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Amarin are expected to decrease in the coming year, from ($0.15) to ($0.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amarin is -5.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amarin is -5.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Amarin has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.81% of the float of Amarin has been sold short.

Short Interest Ratio / Days to Cover

Amarin has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Amarin has recently decreased by 7.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amarin does not currently pay a dividend.

Dividend Growth

Amarin does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.81% of the float of Amarin has been sold short.

Short Interest Ratio / Days to Cover

Amarin has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Amarin has recently decreased by 7.57%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.63

News Sentiment

Amarin has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Amarin this week, compared to 3 articles on an average week.

Search Interest

12 people have searched for AMRN on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Amarin to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Amarin insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.30% of the stock of Amarin is held by insiders.

Percentage Held by Institutions

Only 22.25% of the stock of Amarin is held by institutions.

AMRN Stock Analysis - Frequently Asked Questions

How have AMRN shares performed this year?

Amarin's stock was trading at $9.70 at the start of the year. Since then, AMRN stock has increased by 103.3% and is now trading at $19.72.

How were Amarin's earnings last quarter?

Amarin Corporation PLC (NASDAQ:AMRN) released its quarterly earnings data on Wednesday, July, 30th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.63. The biopharmaceutical company had revenue of $72.74 million for the quarter, compared to analyst estimates of $45.45 million. Amarin had a negative trailing twelve-month return on equity of 21.18% and a negative net margin of 47.22%.
Read the conference call transcript.

When did Amarin's stock split?

Shares of Amarin reverse split on the morning of Friday, April 11th 2025.The 1-20 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Does Amarin have any subsidiaries?

Amarin subsidiaries include these companies: Ester Neurosciences, Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc., Amarin Switzerland GmbH, Amarin UK Limited, and Ester Neurosciences Limited.

How do I buy shares of Amarin?

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amarin investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 7/30/2025
• Today: 10/24/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AMRN
• CIK: 897448
• Web: www.amarincorp.com
• Phone: (531) 669-9020
• Fax: N/A
• Employees: 360
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Amarin: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: -39.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$82.18 million
• Net Margins: -47.22%
• Pretax Margin: -44.91%
• Return on Equity: -21.18%
• Return on Assets: -15.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.26
• Quick Ratio: 2.34

Sales & Book Value

• Annual Sales: $228.61 million
• Price / Sales: 1.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $23.62 per share
• Price / Book: 0.83

Miscellaneous

• Outstanding Shares: 20,680,000
• Free Float: 20,000,000
• Market Cap: $407.81 million
• Optionable: Optionable
• Beta: 0.62